
The fund is an actively managed exchange-traded fund (“ETF”) that seeks to attain its investment objective by investing primarily in equity securities of foreign companies. The fund typically invests in foreign companies with market capitalizations (market value of publicly traded equity securities) greater than $5 billion at the time of purchase.
Is BINV's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.

LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), while pausing earlier programs to maximize the probability of success and near-term value creation."- Martin Welschof, CEO BioInvent.

LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets.

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and one partial response (PR) The treatment has been well-tolerated with no safety or tolerability concerns Study now expanding to additional clinical investigational sites and patient enrollment on track with further Phase 2a results expected by mid-2025 BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces promising initial clinical response data from the two enrolled patients in the triple combination arm of the Phase 1/2a study of its anti-FcyRIIB antibody, BI-1206, combined with rituximab and AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence® (acalabrutinib), in non-Hodgkin's lymphoma (NHL). The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses.
Brandes International might as well use the tag line "we buy ugly stocks." They are a deep contrarian value manager. The firm's success dates back to last century, and it investment success over the decades made it founder a billionaire philanthropist. Top value investors like Charles Brandes and John Templeton focused on buying portfolios of non-US stocks with low turnover for long-term compounding returns.